Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1272-1281 , September 2010

The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia

  • Yu-Feng Lin

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Yu-Feng Lin, DrPH, Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.
    • ,
  • David R. Lairson

      Affiliations

    • School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas
    • ,
  • Wenyaw Chan

      Affiliations

    • School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas
    • ,
  • Xianglin L. Du

      Affiliations

    • School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas
    • ,
  • Kathryn S. Leung

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Alana A. Kennedy-Nasser

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Caridad A. Martinez

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Stephen M. Gottschalk

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Catherine M. Bollard

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Helen E. Heslop

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Malcolm K. Brenner

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
    • ,
  • Robert A. Krance

      Affiliations

    • Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

Received 13 November 2009 ,Accepted 16 March 2010.

References 

  1. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–357
  2. To LB, Roberts MM, Haylock DN, et al. Comparison of heamatological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992;9:277–284
  3. Roberts MM, To LB, Gillis D, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant. 1993;12:469–475
  4. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood. 1995;86:1228–1234
  5. Nash RA, Piñeiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996;88:3634–3641
  6. Anasetti C, Etzioni R, Petersdorf EW, et al. Marrow transplantation from unrelated volunteer donors. Annu Rev Med. 1995;46:169–179
  7. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Eng J Med. 1991;325:1601–1607
  8. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bond marrow transplantation. N Eng J Med. 1991;324:1005–1011
  9. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet. 1995;345:9–13
  10. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–555
  11. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD 34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27:777–783
  12. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) database. Bone Marrow Transplant. 2001;27:689–692
  13. Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood. 2001;98:2900–2908
  14. Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol. 2002;14:160–164
  15. Gluckman E, Locatelli F. Umbilical cord blood transplant. Curr Opin Hematol. 2000;7:353–357
  16. Couban S, Dranitsaris G, Andreou P, et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant. 1998;22:1199–1205
  17. Bennett C, Waters T, Stinson T, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:555–560
  18. van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantations in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 2002;30:243–251
  19. Majhail NS, Mothukuri JM, Brunstein CG, et al. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttranplantation complications. Biol Blood Marrow Transplant. 2009;15:564–573
  20. Costa V, McGregor M, Laneuville P, et al. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value Health. 2007;10:247–255
  21. Hongeng S, Krance RA, Bowen LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancet. 1997;350:767–771
  22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304
  23. Bureau of Labor Statistics. The Consumer Price Index (CPI), 2008. Available from: http://www.bls.gov/cpi/. Accessed January 12, 2009.
  24. Weisberg S. Outliers and influence. In:  Weisberg S editors. Applied Linear Regression. New York: Wiley; 2005;
  25. Mooney CZ, Duval RD. Conclusion. In:  Mooney CZ,  Duval RD editor. Bootstrapping: A Nonparametric Approach to Statistical Inference. Thousand Oaks, CA: Sage; 1993;
  26. Critchfield GC, Willard KE, Connelly DP. Probability sensitivity analysis methods for general decision models. Comput Biomed Res. 1986;19:254–265
  27. Doubilet P, Begg CB, Weinstein MC, et al. Probability sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. 1985;5:157–177
  28. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In:  Gold MR,  Siegel JE,  Russel LB, et al. editor. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996;
  29. Lee SJ, Anasetti C, Kuntz KM, et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998;92:4047–4052
  30. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant. 1995;16:463–470
  31. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute non-lymphocytic leukemia. N Eng J Med. 1989;321:807–812
  32. Messori A, Bonistalli L, Costantini M, et al. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19:275–281
  33. Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol. 1996;14:1413–1420
  34. Beard ME, Inder AB, Allen JR, et al. The costs and benefits of bone marrow transplantation. N Z Med J. 1991;104:303–305
  35. Kouroukis CT, O'Brien BJ, Benger A, et al. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma. 2003;44:29–37
  36. Madero L, González Vincent M, Ramirez M, et al. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant. 2000;26:269–273

 Financial disclosure: See Acknowledgments, page 1279.

PII: S1083-8791(10)00122-9

doi: 10.1016/j.bbmt.2010.03.016

Biology of Blood and Marrow Transplantation
Volume 16, Issue 9 , Pages 1272-1281 , September 2010

Article Tools

* Image Usage & Resolution